.png){kind=icon}
.png){kind=icon}
Return
An orally administered colon-targeted mesalamine nano-prodrug for enhanced therapy and prevention of inflammatory bowel disease
.png){kind=icon}
PRE
AI
X
D
S
S
F
M
L
DOI：10.1016/j.cej.2026.180482.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• A self-assembled azoreductase-responsive nano-prodrug was developed for oral IBD treatment. • A-MPD showed high gastrointestinal stability and resisted premature intestinal degradation. • Negative surface charge promoted selective retention at positively charged inflamed colon sites. • Azoreductase-triggered cleavage enabled on-site mesalamine release in the diseased colon. • A-MPD delivered both potent therapy and prophylactic protection against DSS-induced colitis.
Keywords:
Orally administered
Mesalamine
Nano-prodrug
Colon-targeted
Inflammatory bowel disease
Journal
IF:
13.2
Papers:
7.2W
Citations:
48.5W
Organization
Cited Papers